Sorafenib exposure decreases over time in patients with hepatocellular carcinoma (Q82263349)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

hepatocellular carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Benoit Rousseau

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

6

Guillaume Dumas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

4

Romain Coriat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Jennifer Arrondeau

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Pascaline Boudou-Rouquette

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Stanislas Ropert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Manuel J Rodrigues

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Benoit Blanchet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

François Goldwasser

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

29 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

2046-2049

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22038662%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-011-9764-8

15 January 2020

exact match

0 references

cites work

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

12 December 2020

Imatinib plasma levels: correlation with clinical benefit in GIST patients

1 reference

12 December 2020

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

1 reference

12 December 2020

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

1 reference

12 December 2020

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

1 reference

12 December 2020

The role of imatinib plasma level testing in gastrointestinal stromal tumor

1 reference

12 December 2020

Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

1 reference

12 December 2020

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economi

1 reference

12 December 2020

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

12 December 2020

In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein

1 reference

12 December 2020